Yazar "Trojano, Maria" için listeleme
-
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman, Timothy; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Butzkueven, Helmut (Lippincott Williams & Wilkins, 2018)… -
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Luis Sanchez-Menoyo, Jose (Amer Medical Assoc, 2015)IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is ... -
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, Francois; Van Pesch, Vincent (Sage Publications Ltd, 2016)Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis ... -
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Kister, Ilya; Spelman, Tim; Patti, Francesco; Duquette, Pierre; Trojano, Maria; Izquierdo, Guillermo; Butzkueven, Helmut (Elsevier Science Bv, 2018)Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed ... -
Risk of secondary progressive multiple sclerosis: A longitudinal study
Fambiatos, Adam; Jokubaitis, Vilija; Horakova, Dana; Havrdova, Eva Kubala; Trojano, Maria; Prat, Alexandre; Turkoglu, Recai (Sage Publications Ltd, 2020)Background: The risk factors for conversion from relapsing-remitting to secondary progressive multiple sclerosis remain highly contested. Objective: The aim of this study was to determine the demographic, clinical and ... -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ...
